Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

November 24, 2020November 24, 2020

Phase 1 Trial Will Test Oral PTC518 Candidate Therapy; First Results Due Early 2021

News

A Phase 1 trial will evaluate PTC Therapeutic’s PTC518, its investigational therapy for Huntington’s disease, in healthy volunteers, the company announced. The trial’s first results are expected in the first half ... Read more

October 20, 2020October 20, 2020

FDA Puts Voyager’s Gene Therapy Candidate VY-HTT01 on Clinical Hold

News

The U.S. Food and Drug Administration (FDA) is putting on hold Voyager Therapeutics’ request to test VY-HTT01, its investigational gene therapy for Huntington’s disease, in a clinical trial. The clinical hold will be kept ... Read more

July 14, 2020July 14, 2020

Natural History Study of Huntington’s Starts Enrolling Participants

News

The first patients have been enrolled in a clinical study of the natural history of Huntington’s disease (HD) and its biomarkers, to better inform how to measure and monitor early ... Read more

July 7, 2020July 7, 2020

AFFiRiS’ New Antibody May Help Halt HD Progression, Early Data Suggests

News

AFFiRiS’ C6-17, a candidate monoclonal antibody for the treatment of Huntington’s disease, is able to target and halt the spread of mutant huntingtin protein — the underlying cause of the neurodegenerative disorder ... Read more

June 30, 2020June 30, 2020

AMT-130, uniQure’s Gene Therapy, Given to First Patient Group in Trial

News

A Phase 1/2 clinical trial evaluating AMT-130 as a potential gene therapy for Huntington’s disease has “treated” its first two patients, uniQure announced. One person was given AMT-130 and the other a sham surgery as ... Read more

June 2, 2020June 2, 2020

Pepinemab Clinical Trial Ongoing; Top-line Results Coming Later this Year

News

Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in all 265 patients ... Read more

April 28, 2020April 28, 2020

Enrollment Complete for GENERATION HD1 Trial Testing Tominersen for Huntington’s

News

Roche has completed patient enrollment for its Phase 3 GENERATION HD1 clinical trial evaluating the potential of tominersen to delay the progression of Huntington’s disease. A total of 791 adult patients across ... Read more

March 12, 2020March 12, 2020

Roche Suspends Phase 1 Trial Testing Tominersen (RG6042) for Huntington’s

News

A Phase 1 clinical trial testing Roche’s investigational therapy tominersen for Huntington’s disease has been placed on hold after two cases of infection were found during the study. The infections were ... Read more

March 10, 2020March 10, 2020

Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds

Huntington's Disease News, News

The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000 rare diseases are still lacking ... Read more

March 10, 2020March 10, 2020

UniQure Presents More Data Supporting the Effectiveness of Gene Therapy Candidate AMT-130

News

New preclinical data continues to support uniQure’s AMT-130 investigational gene therapy for Huntington’s disease. Results reveal the therapy lowered the levels of toxic huntingtin protein in nerve cells derived from Huntington’s ... Read more